Cancervaccine development has sustained yet more blows with the early termination of Argos Therapeutics Inc.'s pivotal trial of the dendritic vaccine rocapuldencel-T in metastatic kidney cancer and Agenus Inc.'s Prophage G-200 in a National Cancer Institute (NCI) Phase II study of glioblastoma, in both cases for futility due to unlikelihood of improving overall survival.
Argos' announcement came Feb. 22, when the company said that an independent data monitoring committee (IDMC) recommended during an interim...






